CION Ameerpet
Treatment Explained · Reviewed by CION Oncologists · NABH Accredited
Progestin Therapy — Putting Back the Missing Brake
Endometrial hyperplasia happens because oestrogen has been telling the lining of the womb to grow with nothing telling it to stop. Progestin is the class of hormone that does the stopping — and treatment is, quite literally, supplying what was missing. That is why it works, and why it is a hormone rather than an operation. This page covers what the treatment does, the difference between having it delivered by a device or by tablets, what the side effects genuinely are, and the part women most often get wrong: how success is actually measured.
- It opposes oestrogen directly — the growth signal is countered rather than suppressed indirectly
- The device is first-line — high local dose, far less reaching the rest of you, nothing to remember
- Early irregular bleeding is expected — and is the commonest reason women stop too soon
- Success is judged by biopsy — not by the bleeding settling, which happens much earlier
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Device or Tablets — and Why It Matters
Both deliver a progestin. They do it in quite different ways, and current guidance has a clear preference.
| Hormone-releasing device | Oral progestin | |
|---|---|---|
| How it reaches the lining | Released directly into the uterine cavity, so the endometrium receives a very high local concentration. | Absorbed from the gut, circulated through the whole body, and reaches the lining as part of that circulation. |
| Systemic exposure | Low. Much less hormone reaches the rest of the body, so systemic side effects are generally milder. | Higher, which is why bloating, breast tenderness and mood effects are reported more often. |
| Depends on remembering | No. Once fitted it works continuously, which removes the commonest cause of treatment failure. | Yes. Missed doses are frequent, entirely human, and a recognised reason a lining does not respond. |
| Regression rates | Higher in comparative studies, which is the main reason guidance favours it as first-line. | Effective, and less so than the device in direct comparisons. |
| When it is not suitable | A distorted cavity from large fibroids, current pelvic infection, or a woman who declines a device. | Where adherence is genuinely difficult, or where systemic side effects are poorly tolerated. |
| Getting started | Fitted in an outpatient clinic in a few minutes, without general anaesthetic. See the hormone IUD. | A prescription, started immediately, with the regimen set by your clinician. |
On naming. Progestin is a class of hormone, not one drug — several different progestins are used, at different doses and by different routes, and which one suits you is an individual clinical decision. These pages describe treatment by class rather than naming individual medicines. If you would like the specifics of what you have been prescribed explained, that is a reasonable thing to ask at your appointment.
Did You Know? Progestin does not merely stop the lining growing — it actively reverses what has already happened. Under sustained progestin exposure the overgrown glands stop dividing, mature, and then progressively shrink, so a lining that was crowded and irregular can return to a thin, quiet state over months. This is why hyperplasia without atypia regresses in most women who complete treatment, and why the treatment for a precancerous condition can reasonably be a device fitted in an outpatient clinic. It is also why the effect takes months rather than weeks: the tissue has to remodel, and remodelling is slower than the symptom relief that arrives first. Sources: RCOG / BSGE Green-top Guideline No. 67 on the management of endometrial hyperplasia; World Health Organization classification of tumours of female reproductive organs; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
How Success Is Actually Judged
This is the single most important section on the page, because it is where treatment most often quietly fails.
Bleeding usually improves within the first few months. The woman feels well, the symptom that brought her in has gone, and the repeat biopsy starts to seem unnecessary. But the lining can still show hyperplasia after the bleeding has stopped — the symptom and the histology are two different things.
- Repeat sampling is the measure. Guidance is explicit: treatment is judged by repeat endometrial biopsy, not by symptom resolution. The interval and duration depend on whether atypia was present at diagnosis.
- One normal result is not the finish line. Sampling continues until consecutive normal results are obtained — usually meaning samples across the first year rather than a single check.
- Treatment often continues after regression. Particularly where the underlying cause is unchanged. Removing the device as soon as the lining clears returns it to the conditions that produced the problem.
- Failure to respond has a plan attached. If the lining has not cleared within the agreed window, the next step is a change of route or dose, or — where atypia is present — surgery. That endpoint should be agreed at the start rather than negotiated later.
For the schedule in detail, see follow-up and biopsy monitoring.
On Progestin and Not Sure When the Next Biopsy Is Due?
That appointment is the whole point of the plan, and it is the one most often lost. We will set out a schedule you can actually follow.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
The Bleeding Stopping Is Not the Same as the Lining Clearing
One happens in months, the other is confirmed by a biopsy. Both matter, and only one of them is the goal.
What to expect
Side Effects, and What Can Be Done About Them
None of these should simply be endured. Most have a practical answer, and stopping treatment because of an unmanaged side effect is the worst of both outcomes.
Irregular bleeding in the first months
The commonest effect and the one that most often causes women to abandon treatment. Unpredictable spotting and light bleeding are expected in the early months, because the lining is being stabilised rather than because anything is wrong. It usually settles, and many women end up with much lighter periods or none at all. What does need reporting is bleeding that is heavy rather than spotting, or bleeding that starts again after having settled — that is a different pattern and warrants assessment rather than reassurance.
Bloating, breast tenderness and mood change
Reported more often with oral progestin than with a device, because more hormone reaches the rest of the body. They tend to be worst in the first weeks and to settle. Where they persist and are genuinely affecting your life, that is a reason to discuss switching route rather than to stop treatment — moving from tablets to a device substantially reduces systemic exposure and often resolves these effects while keeping the endometrial treatment intact.
Cramping after a device is fitted
Cramping for a day or two after fitting is normal, comparable to strong period pain, and settles with simple pain relief. Cramping that is severe, that worsens rather than improving, or that comes with fever or offensive discharge is different and should be reported — infection after fitting is uncommon but treatable and worth catching early.
The device being expelled without you knowing
This deserves particular attention because it is silent. A hormone-releasing device can be partly or completely expelled, most often in the first months, and if that happens the lining is effectively untreated while everyone involved believes it is being treated. Unusually heavy bleeding, new cramping, or threads that feel different or absent are all reasons to have the position checked. It is a quick check and worth asking for rather than assuming.
Weight change
Frequently attributed to progestin treatment and the evidence for a substantial effect is weaker than most people assume, particularly for the device where systemic exposure is low. That said, it is worth raising rather than dismissing, because weight matters a great deal in this condition specifically — excess weight is the main driver of the hyperplasia in most women, so anything affecting it is clinically relevant rather than cosmetic. See obesity and endometrial cancer.
Headaches and skin changes
Less common, generally mild, and usually settling over the first months. As with the other systemic effects, persistence is a reason to consider a different progestin or a different route rather than to abandon treatment. The important principle across all of these is that the treatment is worth persisting with and that persistence is much easier when the side effects are actively managed rather than tolerated in silence.
Struggling With Side Effects and Thinking of Stopping?
There is usually a change of route or dose that keeps the treatment and loses the problem. Worth a conversation first. The opinion is free.
How the Plan Differs by Type
Progestin is used for both categories of hyperplasia, and the intent behind it is quite different in each.
- Hyperplasia without atypia — progestin is the treatment. First-line, expected to clear the lining in most women, with surgery reserved for failure or relapse. See hyperplasia without atypia.
- Atypical hyperplasia — progestin substitutes for surgery. Here hysterectomy is the standard recommendation, and high-dose progestin with intensive surveillance is the alternative for women who want to conceive or who cannot safely have an operation. Same drug class, quite different context. See atypical hyperplasia.
- Fertility-sparing treatment uses higher doses and closer surveillance. Sampling every few months, an agreed point at which failure means surgery, and early referral to reproductive medicine. See fertility-sparing progestin therapy.
- Prevention uses the same principle at lower intensity. In women with infrequent cycles, ensuring regular progestogen exposure prevents hyperplasia arising in the first place. See PCOS and endometrial cancer.
Why the Follow-Up Matters as Much as the Prescription
Progestin works. Whether it has worked is a separate question, and it needs someone whose job it is to ask.
Scan and biopsy in one visit
Follow-up you can actually keep
Fertility taken seriously
45-minute consultations
Survivorship care that is actually offered
Decisions for healing, not billing
Take The Next Step
Do Not Stop Treatment Because of a Side Effect
Come and say so instead. There is nearly always a version of this treatment you can tolerate.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Progestin Therapy for Hyperplasia — Frequently Asked Questions
How does progestin treat endometrial hyperplasia?
By supplying the hormone the lining has been missing. Endometrial hyperplasia develops when oestrogen stimulates the endometrium to grow without enough progesterone to stop it. Progestins are the class of hormones that oppose that effect: they bind progesterone receptors in the endometrial tissue, halt glandular proliferation, induce maturation, and ultimately cause the overgrown lining to thin. This is not merely suppression — it actively reverses changes that have already occurred, which is why hyperplasia without atypia regresses in most women who complete treatment. It also explains why the effect takes months rather than weeks: the tissue has to remodel, and that is slower than the symptom relief which arrives first.
Is the device better than tablets?
Current guidance favours a hormone-releasing intrauterine device as first-line treatment, and there are three reasons. It places the progestin directly against the lining, achieving a very high local concentration while much less reaches the rest of the body, so systemic side effects such as bloating, breast tenderness and mood change are generally milder. It does not depend on remembering to take anything, which removes one of the commonest causes of treatment failure. And in direct comparisons it achieves higher regression rates. Oral progestin remains a reasonable option where a device cannot be fitted, where the uterine cavity is distorted by fibroids, or where a woman would rather not have one.
How long will I need to be on it?
Longer than the symptoms take to settle, which is the source of most confusion. Bleeding usually improves within the first few months, but treatment is not judged on that — repeat endometrial biopsies are taken during treatment, and guidance recommends continuing until consecutive normal samples confirm the hyperplasia has resolved, typically meaning sampling across the first year. Beyond that, a hormone-releasing device is often left in place for a prolonged period after regression, particularly where the underlying cause has not changed, because removing it returns the lining to exactly the hormonal conditions that produced the problem in the first place.
The bleeding has stopped. Does that mean it has worked?
Not necessarily, and this is the most important caveat about this treatment. Bleeding and histology are two different things, and the lining can still show hyperplasia after the symptom that led to its discovery has resolved. Guidance is explicit that treatment success is established by repeat endometrial sampling rather than by symptom improvement, and that sampling continues until consecutive normal results are obtained. The commonest way hyperplasia treatment fails is not that the hormone does not work — it is that the woman feels well, stops attending, and nobody ever confirms whether the lining actually cleared.
I am getting side effects. Should I stop?
Come and discuss it rather than stopping, because there is nearly always a version of this treatment you can tolerate. Irregular spotting in the early months is expected and usually settles — it is the commonest reason women abandon treatment unnecessarily. Bloating, breast tenderness and mood change are reported more often with tablets than with a device, and switching route substantially reduces systemic exposure while keeping the endometrial treatment intact. Different progestins also differ in tolerability. Stopping treatment because of an unmanaged side effect leaves you with the hyperplasia and without the benefit, which is the worst of both outcomes.
Medical disclaimer: This page describes progestin therapy for endometrial hyperplasia in general terms and is reviewed by a CION oncologist, following RCOG/BSGE Green-top Guideline No. 67 and current NCCN guidance. It describes treatment by hormone class rather than naming individual medicines, because the choice of preparation, dose and route is an individual clinical decision. It is not advice about your own treatment. Do not stop prescribed treatment on the basis of this page; raise any difficulty with the clinician managing your care.